drugset / Trial / NCT04917250
GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of GPED (gemcitabine, pegaspargase, etoposide, and dexamethasone) regimen in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients
Timeline
- Start
- 2020-03-20
- Primary completion
- 2021-06-30
- Completion
- 2021-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 20 mg | Intravenous |
| Subject | Etoposide | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Pegaspargase | Protein / enzyme biologic | 2500 iu/kg | — |